Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Advertisements

Primary Care Challenges in Depression - To Treat or Refer?

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

The Role of Anticholinergic Therapy in Moderate to Severe Asthma

Optimizing Outcomes in Short Bowel Syndrome With IF

Prophylaxis Considerations for Teenagers and Young Adults With Severe Hemophilia.

Long-Term Treatment of VTE: Case Studies

Thrombosis, Cancer, and NOACs

MANAGING GLAUCOMA:.

RSV Bronchiolitis.

Protecting Patients With Varicose Veins

Epidemiology Venous Pathophysiology Etiology.

Medication Nonadherence in Gout

Extended Half-life Factor Products in the Management of Hemophilia

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Managing Hereditary Angioedema

Individualizing Prophylaxis in Hemophilia

Hot Topics in Hemophilia Nursing

Issues in the Management of Hemophilia: A Best Practice Series

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Surveying the Safety of NOACs in the Real World

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Tailoring Hemophilia Prophylaxis Therapy

When Would You Use Single Inhaler Triple Therapy in COPD?

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Is RA Treatment Addressing the Real Needs of Patients?

Individualizing Factor Replacement Therapy for Patients With Hemophilia.

EHL Technologies in Hemophilia Care

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Exploring Personalized Prophylaxis in Hemophilia A

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Perspectives on the Impact of Inflammation in OA

Practical Considerations to Extend Treatment for VTE

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Program Goals. Technological Advances in Longer-Acting Factor Replacement Therapy for Hemophilia.

Updates in Cardiovascular Medicine

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Multidisciplinary Approaches to Managing Hemophilia

What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Long-Term Treatment of VTE: Case Studies

Factor Xa Inhibitors in PAD

Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B.

IgG-Fc Fusion Proteins and Immunomodulation: What Does the Science Tell Us?

Expert Perspectives on Postoperative Ileus

Managing Age-Related Clinical Issues in Hemophilia

Extended Half-life Factor Products in the Management of Hemophilia

Updates From the 2015 Meetings in Hemophilia

Current Challenges in Managing Hemophilia

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

Optimizing Joint Health in Hemophilia

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Incorporating Prostacyclins Into Practice

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Assessing the Burden of Hyperkalemia

Selecting Treatment Approaches in Hemophilia

Assessing the Burden of Hyperkalemia

Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products?

Rational Pharmacotherapy Selection for Insomnia

Binge Eating Disorder.

What's New in PAH?.

My PAH Patient.

Examining the Role of Pharmacokinetics in Hemophilia

Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.

Navigating the Journey

Treating Pulmonary Embolism Today

Diagnosing HFpEF: What Every Cardiologist Needs to Know

Presentation transcript:

Etiology and Incidence

Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface

Pathophysiology (cont) Hemophilia is due to a defect in thrombin generation on the platelet surface

Clinical Presentation

Potential Clinical Sequelae of Poorly Managed Hemophilia

Clinical Classification

Primary Therapy Clotting Factor Replacement

Prophylaxis Protocols Definitions

Prophylaxis Some Related Questions

Joint Outcome Study Results

Prophylaxis in Adolescents and Adults SPINART Study

SPINART Results

Prophylaxis* Initiation and Dosing

Inhibitors

Adherence to Prophylaxis (cont)

HTCs

HTC vs non-HTC Effect on Mortality

Extended Half-Life Clotting Factor Formulations

Optimizing Hemophilia Management Through Individualized Treatment

Assessment of Joint Health Hemophilia Joint Health Scores

Summary

Abbreviations

References

References

References

References

References